Real-world effectiveness of add-on fremanezumab in patients receiving onabotulinumtoxinA for the prevention of chronic migraine in a US tertiary headache center: A retrospective chart review study

• Autori principali: Hsiangkuo Yuan (Autore), Fred Cohen (Autore), Maurice T Driessen (Autore), Lynda J Krasenbaum (Autore), Mario Ortega (Autore), Mary Hopkins (Autore), Michael J Marmura (Autore)
• Natura: Libro
• Pubblicazione: SAGE Publishing, 2024-03-01T00:00:00Z.
• Soggetti: article
• Accesso online: Connect to this object online.

Background: Concomitant fremanezumab, a calcitonin gene-related peptide (CGRP) pathway monoclonal antibody (mAb), and onabotulinumtoxinA (onabotA) improve treatment response compared with onabotA alone in patients with chronic migraine (CM). Methods: This was a single-center, retrospective, observat...